Search Results 761-770 of 18333 for alopecia

1. Study of DF9001 in Patients With Advanced Solid Tumors - Mayo Clinic

   0; however, alopecia ≤Grade 2, endocrinopathies ≤Grade 2, and sensory neuropathy ≤Grade 2 is acceptable. 12. Participants who have received an anti-PD-(L ...

2. Facial fillers for wrinkles - Doctors & Departments - Mayo Clinic

   ... Alopecia areata, Oral ulcerative condition, Facial volume loss, Vulvar disorder. Show more areas of focus for Alison J. Bruce, M.B., Ch.B.

3. A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma or non-Hodgkin Lymphoma - Mayo Clinic

   ... alopecia. Patients with clinical signs of central nervous system (CNS) involvement of MM. Patients with known or suspected light chain amyloidosis of any ...

4. A Study to Determine the Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies - Mayo Clinic

   03 Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria with the exception of alopecia. Subjects with irreversible toxicity that is not ...

5. MEDI5395 Advanced Solid Tumors - Clinical Trials

   Participation eligibility · Vitiligo or alopecia; · Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; · Any chronic skin condition ...

6. Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas - Mayo Clinic

   Patients who have not recovered to Grade 1 or baseline from adverse events related to prior therapy excluding lymphopenia, alopecia, peripheral neuropathy ...

7. A Study Of 177Lu-FAP-2286 In Advanced Solid Tumors - Mayo Clinic

   0 (or higher) Grade 1, with the exception for alopecia and vitiligo. Exclusion criteria 6 and 7 are removed with Protocol Amendment 7. 8. Impaired cardiac ...

8. Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) - Mayo Clinic

   Toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet improved to NCI-CTCAE version 5.0 Grade ≤ 1 or baseline.

9. Novel Study Interventions and Combinations in Participants with Colorectal Cancer - Mayo Clinic

   Any unresolved toxicity NCI CTCAE Grade ≥ 2 from a previous anticancer therapy, with the exception of alopecia, vitiligo, and the laboratory values defined ...

10. Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer - Mayo Clinic

    Patient must be able to have recovered from all toxicities associated with chemoradiotherapy for anal cancer, to Grade ≤ 1 with the exception of alopecia.